Investigating the Prevalence and Risk Factors for Sarcopenia Amongst Adults Seeking Treatment for Obesity
Recruiting · NCT07541677 · Observational (researchers observe without assigning treatment) · Lead sponsor: Singapore General Hospital
View the official record on ClinicalTrials.gov →What this trial is about
Sarcopenia, a condition where individuals lose muscle mass and strength, is associated with poorer health and function. While aging is a well-known cause of sarcopenia, obesity is increasingly recognised as a significant factor. When sarcopenia and obesity occur together, it can result in more severe health problems. This is especially concerning because weight loss, the treatment for obesity, can further reduce muscle mass and potentially worsen the situation. Despite this, it is unknown how common sarcopenia is among people with obesity, as only a few studies have looked into this using the most accurate diagnostic criteria, showing a prevalence of 4-13%. In this study, the investigators will examine the prevalence of sarcopenia in 300 adults with obesity at a specialized Obesity Center. The investigators expect to find a higher prevalence among Asian participants due to differences in body composition compared to other ethnic groups. The investigators will also explore various factors that might be linked to sarcopenia in these individuals, such as age, gender, race, body mass index, smoking and alcohol use, medical conditions, medications, physical activity, aerobic capacity, and dietary protein intake. Some of these factors could help in identifying those at risk of sarcopenia and could be targeted for future treatments. Currently, screening for sarcopenia is not a standard part of routine obesity care as it requires specialized equipment and trained staff. By determining how common sarcopenia is in people with obesity, this study will help healthcare providers better understand the problem and allocate resources effectively. Identifying factors associated with sarcopenia will also help streamline diagnosis and monitoring for those at risk.
Who can take part
Inclusion criteria
- body mass index ≥ 27.5kg/m2
- able to provide informed consent.
Exclusion criteria
- unable to undergo the physical function tests (handgrip strength testing and chair-stand tests)
- pregnant women
- history of bariatric procedures or surgeries
- on medications for treatment of obesity (glucagon-like peptide 1 receptor agonists, phentermine, naltrexone-bupropion, orlistat)
Where it is running
1 location listed.
- Singapore General Hospital - Singapore, Singapore